CRISPR Therapeutics (CRSP) PT Raised to $56 at Bernstein SocGen Group
Bernstein SocGen Group analyst William Pickering raised the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $56.00 (from $50.00) while maintaining a Market Perform rating.